CA3150975A1 - Topical treatment of vitiligo by a jak inhibitor - Google Patents

Topical treatment of vitiligo by a jak inhibitor Download PDF

Info

Publication number
CA3150975A1
CA3150975A1 CA3150975A CA3150975A CA3150975A1 CA 3150975 A1 CA3150975 A1 CA 3150975A1 CA 3150975 A CA3150975 A CA 3150975A CA 3150975 A CA3150975 A CA 3150975A CA 3150975 A1 CA3150975 A1 CA 3150975A1
Authority
CA
Canada
Prior art keywords
week
patient
vitiligo
ruxolitinib
area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150975A
Other languages
English (en)
French (fr)
Inventor
Kathleen Butler
Jim Lee
Kang Sun
Fiona Kuo
Michael Howell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73651112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3150975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CA3150975A1 publication Critical patent/CA3150975A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3150975A 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor Pending CA3150975A1 (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201962859584P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859495P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US62/859,532 2019-06-10
US62/859,495 2019-06-10
US62/859,584 2019-06-10
US62/859,506 2019-06-10
US62/859,601 2019-06-10
US201962894514P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894564P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894496P 2019-08-30 2019-08-30
US62/894,581 2019-08-30
US62/894,496 2019-08-30
US62/894,514 2019-08-30
US62/894,541 2019-08-30
US62/894,564 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US62/911,845 2019-10-07
US202062967879P 2020-01-30 2020-01-30
US62/967,879 2020-01-30
PCT/US2020/036985 WO2020252012A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Publications (1)

Publication Number Publication Date
CA3150975A1 true CA3150975A1 (en) 2020-12-17

Family

ID=73651112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150975A Pending CA3150975A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Country Status (9)

Country Link
US (4) US20200405627A1 (https=)
EP (1) EP3982971A4 (https=)
JP (2) JP7532511B2 (https=)
AU (2) AU2020290995B2 (https=)
CA (1) CA3150975A1 (https=)
IL (1) IL290637A (https=)
MA (1) MA56215A (https=)
TW (1) TW202112377A (https=)
WO (1) WO2020252012A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
JP7532511B2 (ja) 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療
WO2022061351A1 (en) * 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
TW202302104A (zh) * 2021-02-18 2023-01-16 美商阿克拉里斯醫療股份有限公司 Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法
CN117279915A (zh) * 2021-02-18 2023-12-22 阿克拉瑞斯治疗股份有限公司 Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法
EP4389114A4 (en) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd LOCAL TOPICAL FORMULATION CONTAINING A JAK INHIBITOR OR A SALT THEREOF OR A CRYSTALLINE FORM THEREOF, PREPARATION METHOD THEREOF AND CORRESPONDING APPLICATION
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1542768A1 (en) 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
AU2017358703A1 (en) 2016-11-10 2019-05-09 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
JP7532511B2 (ja) * 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療

Also Published As

Publication number Publication date
AU2026200410A1 (en) 2026-02-12
MA56215A (fr) 2022-04-20
US20230355628A1 (en) 2023-11-09
US20200383986A1 (en) 2020-12-10
US20220409622A1 (en) 2022-12-29
WO2020252012A1 (en) 2020-12-17
AU2020290995B2 (en) 2025-12-11
AU2020290995A1 (en) 2022-04-07
US11590138B2 (en) 2023-02-28
TW202112377A (zh) 2021-04-01
JP2024105436A (ja) 2024-08-06
US11602536B2 (en) 2023-03-14
US12233067B2 (en) 2025-02-25
EP3982971A1 (en) 2022-04-20
EP3982971A4 (en) 2023-08-16
IL290637A (en) 2022-04-01
JP7532511B2 (ja) 2024-08-13
US20200405627A1 (en) 2020-12-31
JP2022545568A (ja) 2022-10-27

Similar Documents

Publication Publication Date Title
US12233067B2 (en) Topical treatment of vitiligo by a JAK inhibitor
KR20140004186A (ko) 표면활성제 조성물
US20220387447A1 (en) Formulations of testosterone and methods of treatment therewith
US10258631B2 (en) Formulations of testosterone and methods of treatment therewith
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US12589096B2 (en) Ruxolitinib formulation for reduction of itch in atopic dermatitis
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
WO2019113475A1 (en) Topical ointment formulations and their use in treating skin conditions
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak
AU2019257990B2 (en) Compositions for treating female sexual dysfunction
KR20150095772A (ko) 아토피성 피부염 치료를 위한 피도티모드의 사용
JPH0971539A (ja) 外用鎮痒剤
GB2616294A (en) Composition for use
HK1255629B (en) Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus
HK1255629A1 (zh) 包含马马香材木(ambora)提取物和绿茶提取物的组合物用於治疗银屑病，特应性皮炎，慢性荨麻疹，抗组胺耐药瘙痒症和老年性瘙痒症

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240610

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250917

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251205

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251205